1-20 of 5,566 results for subject:"Clinical trials"
Librarians' tools
- Search time
- 0.304 seconds
- Solr query time
- 0.012 seconds
- Search query
- subject:"Clinical trials"
- We searched for
- subject_t:"Clinical trials" OR subject_ses:90552
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the use of clinical trials for research into pancreatic cancer.
To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the use of clinical trials for research into pancreatic cancer.
I refer the Hon Member to the answer provided on 15 July in response to Question 16704.
To ask the Secretary of State for Health and Social Care, what work her Department is undertaking to (a) support brain cancer suffers and (b) increase the proportion of funding available for clinicial trials and research.
To ask the Secretary of State for Health and Social Care, what work her Department is undertaking to (a) support brain cancer suffers and (b) increase the proportion of funding available for clinicial trials and research.
To ask His Majesty's Government which bodies or officeholders are accountable for figures relating to (1) expenditure on brain tumour research, (2) tumour-specific expenditure, (3) molecular testing and subsequent treatment or clinical trial matching, (4) participation in international clinical trials, and (5) patient outcomes; and where such figures are not...
To ask His Majesty's Government which bodies or officeholders are accountable for figures relating to (1) expenditure on brain tumour research, (2) tumour-specific expenditure, (3) molecular testing and subsequent treatment or clinical trial matching, (4) participation in international clinical trials, and (5) patient outcomes; and where such figures are not...
To ask His Majesty's Government which bodies or officeholders are accountable for (1) collecting, (2) reporting, and (3) publishing data on (a) expenditure on brain tumours, including direct disease-specific research expenditure, (b) molecular profiling, (c) liquid biopsy testing, (d) treatment and clinical trial matching, (e) international trial participation, and (f)...
To ask His Majesty's Government which bodies or officeholders are accountable for (1) collecting, (2) reporting, and (3) publishing data on (a) expenditure on brain tumours, including direct disease-specific research expenditure, (b) molecular profiling, (c) liquid biopsy testing, (d) treatment and clinical trial matching, (e) international trial participation, and (f)...
To ask His Majesty's Government which bodies or officeholders are responsible for (1) reviewing evidence of disparities in brain cancer research investment, research activity, clinical trial opportunities, and patient outcomes between different grades, subtypes, and molecular profiles; (2) deciding whether such disparities require intervention and authorising or directing that intervention;...
To ask His Majesty's Government which bodies or officeholders are responsible for (1) reviewing evidence of disparities in brain cancer research investment, research activity, clinical trial opportunities, and patient outcomes between different grades, subtypes, and molecular profiles; (2) deciding whether such disparities require intervention and authorising or directing that intervention;...
To ask His Majesty's Government which bodies hold data on (1) molecular characteristics and actionable mutations in brain cancers, (2) treatment matching, (3) clinical trial matching, and (4) patient outcomes; whether those data permit assessment of the relationship between molecular diagnosis, treatment or trial matching, and subsequent outcomes; and, if...
To ask His Majesty's Government which bodies hold data on (1) molecular characteristics and actionable mutations in brain cancers, (2) treatment matching, (3) clinical trial matching, and (4) patient outcomes; whether those data permit assessment of the relationship between molecular diagnosis, treatment or trial matching, and subsequent outcomes; and, if...
To ask His Majesty's Government, relating to treatments, clinical trials, and other opportunities outside the United Kingdom that may improve outcomes for brain cancer patients, which bodies or officeholders are responsible for (1) identifying these opportunities; (2) deciding whether they should be pursued; (3) ensuring they are pursued; and (4)...
To ask His Majesty's Government, relating to treatments, clinical trials, and other opportunities outside the United Kingdom that may improve outcomes for brain cancer patients, which bodies or officeholders are responsible for (1) identifying these opportunities; (2) deciding whether they should be pursued; (3) ensuring they are pursued; and (4)...
To ask the Secretary of State for Health and Social Care, if she would consider the potential merits of appointing clinical research nurses to work only on brain cancer clinical trials.
To ask the Secretary of State for Health and Social Care, if she would consider the potential merits of appointing clinical research nurses to work only on brain cancer clinical trials.
The Government recognises the importance of ensuring that National Health Service organisations have the appropriate workforce to support the delivery of clinical trials, including trials of brain cancer treatments.
Decisions about the composition and deployment of clinical research teams are for individual host organisations, based on their research portfolio, clinical priorities, patient population, and workforce requirements. This may include the appointment of research nurses with specialist expertise in particular disease areas where this is appropriate.
The Government does not currently mandate a particular staffing model but provides support with funding through the National Institute of Health and Care Research to develop the capacity and capability to deliver research, expecting host organisations to ensure that they have the appropriate resources and expertise to deliver the clinical research undertaken at their sites.
To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with Nuvation Bio about bringing clinical trials of Safusidenib to the UK for patients with IDH1-mutant Astrocytomas who have previously received radiotherapy and chemotherapy.
To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with Nuvation Bio about bringing clinical trials of Safusidenib to the UK for patients with IDH1-mutant Astrocytomas who have previously received radiotherapy and chemotherapy.
The Department is supporting engagement with commercial sponsors of clinical trials through the National Institute for Health and Care Research (NIHR) Life Sciences Industry Hub. The NIHR Industry Hub provides a single, nationally coordinated pathway for research sponsors like Nuvation Bio to engage with, to set up and deliver commercial clinical trials.
To ask His Majesty's Government how many new brain cancer treatments in each year since 2018 (1) entered a clinical trial in the United Kingdom, (2) obtained a United Kingdom marketing authorisation, (3) became routinely available on the NHS, and (4) were prescribed to NHS patients; what proportion of patients diagnosed...
To ask His Majesty's Government how many new brain cancer treatments in each year since 2018 (1) entered a clinical trial in the United Kingdom, (2) obtained a United Kingdom marketing authorisation, (3) became routinely available on the NHS, and (4) were prescribed to NHS patients; what proportion of patients diagnosed...
Information for the first and third points mentioned is not held centrally. In relation to the second point, one new brain cancer treatment has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency since 2018. This was vorasidenib, which was granted marketing authorisation in September 2025. In relation to the fourth point, the following table shows the total number of items in each calendar year from January 2018 to June 2026 that were dispensed in England regardless of where prescribed, based on the information within the Prescription Costs Analysis for the British National Formulary chemical substances of dabrafenib, trametinib, and vorasidenib:
BNF Chemical Substance | 2018 | 2019 | 2021 | 2023 | 2024 |
Dabrafenib | 1 | 1 | 1 | 2 | |
Trametinib | 1 | 2 | 1 | 1 | 2 |
Source: NHS Business Services Authority (NHSBSA).
Note: NHSBSA does not hold information on patient condition or reasons for why the drug has been prescribed.
No data is available where the year or chemical substance is not included.
To ask the Secretary of State for Health and Social Care, whether she will make representations to NuvationBio to encourage access to the SIGMA Phase 3 trial of Safusideniv for eligible patients at UK hospitals.
To ask the Secretary of State for Health and Social Care, whether she will make representations to NuvationBio to encourage access to the SIGMA Phase 3 trial of Safusideniv for eligible patients at UK hospitals.
The Department is supporting engagement with commercial sponsors of clinical trials through the National Institute for Health and Care Research (NIHR) Life Sciences Industry Hub. The NIHR Industry Hub provides a single, nationally coordinated pathway for research sponsors like Nuvation Bio to engage with, to set up and deliver commercial clinical trials.
To ask the Secretary of State for Health and Social Care, what recent discussions her Department has had with (a) patients and (b) medical professionals on increasing (i) investment and (ii) clinical trials into cancer treatments.
To ask the Secretary of State for Health and Social Care, what recent discussions her Department has had with (a) patients and (b) medical professionals on increasing (i) investment and (ii) clinical trials into cancer treatments.
I refer the Hon Member to the National Cancer Plan for England, published in February, which sets out the steps we are taking in a range of areas to improve cancer diagnosis, treatment, and outcomes, including for research and clinical trials. The National Cancer Plan for England is available at the following link:
I also refer the Hon Member to the answer provided on 24 February 2026 to the Hon Member for Sheffield South East to Question 113042.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to expand access to clinical trials for (a) pancreatic cancer patients and (b) patients with cancerous brain tumours.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to expand access to clinical trials for (a) pancreatic cancer patients and (b) patients with cancerous brain tumours.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to clinical trials for people with pancreatic cancer.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to clinical trials for people with pancreatic cancer.
I refer the Hon Member to the answer provided to the Hon Member for Stratford-on-Avon on 15 July 2026 in response to Question 16704.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that patients with pancreatic cancer are automatically linked to available clinical trials.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that patients with pancreatic cancer are automatically linked to available clinical trials.
I refer the Hon Member to the answer provided to the Hon Member for Stratford-on-Avon on 15 July 2026 in response to Question 16704.
To ask the Secretary of State for Health and Social Care, whether the forthcoming 10 Year Workforce Plan will include measures to increase NHS capacity to deliver non-commercial clinical trials.
To ask the Secretary of State for Health and Social Care, whether the forthcoming 10 Year Workforce Plan will include measures to increase NHS capacity to deliver non-commercial clinical trials.
As set out in the Life Sciences Sector Plan and reinforced in the 10-Year Health Plan for England, the Department is committed to cutting the current time it takes to get a clinical trial set up, to under 150 days. I refer the Hon Member to the report, including actions and progress so far against the 150-day target, published by the Government on 9 July 2026, which is available at the following link:
https://www.gov.uk/government/publications/life-sciences-sector-plan-one-year-on
The National Cancer Plan, available at the link below, outlines actions to increase the speed, scale, and reliability of cancer clinical trials in detail:
https://www.gov.uk/government/publications/national-cancer-plan-for-england
The 10-Year Health Plan for England, available at the link below, commits to embedding research as a core component of care:
https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future
An update on the forthcoming 10 Year Workforce Plan will be available in due course.
In July 2026, the Department, through the National Institute for Health and Care Research (NIHR), published the Research Workforce Update for England which aims to ensure that research opportunities and careers are accessible to a broader range of professions and communities, helping to develop a sustainable and inclusive research workforce across all health and social care settings and geographies for the future. The Research Workforce Update for England is available at the following link:
https://www.nihr.ac.uk/research-workforce-update-england
All NIHR personal awards are open to foreign nationals. The Global Talent visa includes certain NIHR personal awards under the recognised list of personal fellowships that allows people to apply for a fast-track visa. Further details available at the following link:
https://royalsociety.org/grants/global-talent-visa-overview/route-2-individual-fellowships/
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to reduce the time taken to open cancer clinical trials in the NHS, and what assessment they have made of the potential impact of delays in opening cancer clinical trials for new treatments.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to reduce the time taken to open cancer clinical trials in the NHS, and what assessment they have made of the potential impact of delays in opening cancer clinical trials for new treatments.
As set out in the Life Sciences Sector Plan and reinforced in the 10-Year Health Plan for England, the Department is committed to cutting the current time it takes to get a clinical trial set up, to under 150 days. I refer the Hon Member to the report, including actions and progress so far against the 150-day target, published by the Government on 9 July 2026, which is available at the following link:
https://www.gov.uk/government/publications/life-sciences-sector-plan-one-year-on
The National Cancer Plan, available at the link below, outlines actions to increase the speed, scale, and reliability of cancer clinical trials in detail:
https://www.gov.uk/government/publications/national-cancer-plan-for-england
The 10-Year Health Plan for England, available at the link below, commits to embedding research as a core component of care:
https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future
An update on the forthcoming 10 Year Workforce Plan will be available in due course.
In July 2026, the Department, through the National Institute for Health and Care Research (NIHR), published the Research Workforce Update for England which aims to ensure that research opportunities and careers are accessible to a broader range of professions and communities, helping to develop a sustainable and inclusive research workforce across all health and social care settings and geographies for the future. The Research Workforce Update for England is available at the following link:
https://www.nihr.ac.uk/research-workforce-update-england
All NIHR personal awards are open to foreign nationals. The Global Talent visa includes certain NIHR personal awards under the recognised list of personal fellowships that allows people to apply for a fast-track visa. Further details available at the following link:
https://royalsociety.org/grants/global-talent-visa-overview/route-2-individual-fellowships/
Absolutely; my hon. Friend has obviously read my speech. What would happen if the new unit identified the CQC itself as the problem? Ministers have not provided good answers to these questions. To be honest, they cannot, because the Government cannot have their cake and eat it. Either HSSIB remains...
Absolutely; my hon. Friend has obviously read my speech. What would happen if the new unit identified the CQC itself as the problem? Ministers have not provided good answers to these questions. To be honest, they cannot, because the Government cannot have their cake and eat it. Either HSSIB remains...
Agreed to on question.
Agreed to on question.
I begin by welcoming the Government’s decision at the start of the summer to pause the application of VAT on medicines donated for free to patients through compassionate access, early access and related schemes. The health charities, patients and industry bodies that I have worked with are grateful to Ministers...
I begin by welcoming the Government’s decision at the start of the summer to pause the application of VAT on medicines donated for free to patients through compassionate access, early access and related schemes. The health charities, patients and industry bodies that I have worked with are grateful to Ministers...